Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.38 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12102748 | 1.00 | ALDH1A1 (0.49) | ALDH1A1KMT2AHSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL21042943 | 1.00 | ALDH1A1 (0.49) | ALDH1A1KMT2AHSD17B10SMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL21612902 | 0.98 | ALDH1A1 (0.51) | ALDH1A1KMT2AHSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL11977462 | 0.88 | LMNA (0.46) | ALDH1A1POLBLMNA | |
| SCHEMBL15188004 | 0.88 | LMNA (0.46) | ALDH1A1POLBLMNA | |
| SCHEMBL12102740 | 0.88 | LMNA (0.46) | ALDH1A1POLBLMNA | |
| SCHEMBL11923163 | 0.85 | ALDH1A1 (0.36) | ALDH1A1KMT2AHSD17B10SMN1; SMN2MEN1 | |
| SCHEMBL4971987 | 0.85 | ALDH1A1 (0.36) | ALDH1A1KMT2AHSD17B10SMN1; SMN2MEN1 | |
| SCHEMBL8258796 | 0.83 | ALDH1A1 (0.46) | ALDH1A1KMT2AHSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL18501697 | 0.83 | ATM (0.34) | ALDH1A1KMT2AHSD17B10SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230192713-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192713-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| CN-115710274-A | IRAK4 degradation agent, preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2023-02-24 | — | — | CN | disclosed |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-04-14 | — | — | US | disclosed |
| US-20210347785-A1 | PREPARATION AND APPLICATION OF AROMATIC COMPOUND HAVING IMMUNOREGULATORY FUNCTION | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2021-11-11 | — | — | US | disclosed |
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2021-11-02 | — | — | US | disclosed |
| US-20210214375-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2021-07-15 | — | — | US | disclosed |
| US-10781211-B2 | Spirocycle compounds and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20110269738-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-20110269738-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-20110150864-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | US | disclosed |
| US-20100152197-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| US-20090258858-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| US-20090258858-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-7405210-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | OSI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | BRADLEY STUART E | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781211-B2 | Spirocycle compounds and methods of making and using same | ABHD6, ABHD16A, ACSL6 | ALDH1A1 932/4885KMT2A 3691/4885HSD17B10 237/4885 |
| US-20110269738-A1 | COMPOUNDS | CYP11B2, CYP11B1, GPR119 | ALDH1A1 842/4885KMT2A 4470/4885HSD17B10 387/4885 |
| US-20230192713-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | ALDH1A1 301/4885KMT2A 2794/4885HSD17B10 712/4885 |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | MGLL, LIPA, PNLIP | ALDH1A1 2174/4885KMT2A 2542/4885HSD17B10 393/4885 |
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | OPRL1, MGLL, VKORC1L1 | ALDH1A1 1022/4885KMT2A 4106/4885HSD17B10 670/4885 |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | ALDH1A1 301/4885KMT2A 2794/4885HSD17B10 712/4885 |
| US-20100152197-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | CCR2, CCR5, CNR2 | ALDH1A1 1115/4885KMT2A 2528/4885HSD17B10 1902/4885 |
| US-20090258858-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | CHRM3, CHRNG, CHRM2 | ALDH1A1 2948/4885KMT2A 2510/4885HSD17B10 2972/4885 |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | PYGL, PYGM, PYGB | ALDH1A1 720/4885KMT2A 2476/4885HSD17B10 124/4885 |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | ALDH1A1 720/4885KMT2A 2476/4885HSD17B10 124/4885 |
| US-20210214375-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | OPRL1, MGLL, OPRK1 | ALDH1A1 1735/4885KMT2A 4253/4885HSD17B10 931/4885 |
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABHD6, ABHD16A, ACSL6 | ALDH1A1 932/4885KMT2A 3691/4885HSD17B10 237/4885 |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | LSS, ABCG2, SELL | ALDH1A1 533/4885KMT2A 4667/4885HSD17B10 2891/4885 |
| US-20210347785-A1 | PREPARATION AND APPLICATION OF AROMATIC COMPOUND HAVING IMMUNOREGULATORY FUNCTION | CD274, PDCD1, PDCD1LG2 | ALDH1A1 235/4885KMT2A 1064/4885HSD17B10 3517/4885 |
| US-20110150864-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, IGF1R | ALDH1A1 2302/4885KMT2A 1749/4885HSD17B10 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.